📌Effect of #SacubitrilValsartan on investigator-reported ventricular arrhythmias in #PARADIGMHF
🔸SV ↘️ VA in HFrEF
#CardioEd #CardioTwitter #ePeeps

#PARADIGMHF TRIAL ADDITIONAL FINDINGS

📌Variation in Renal Function Following Transition to #SacubitrilValsartan in 👥 w/ #HeartFailure

#CardioTwitter #CardioEd #PARADIGMHF #PARAGONHF

This drug needs a name. #PARADIGMHF #miltonpacker

Very proud to share this analysis of #PARADIGMHF on anthropometric measures and adverse outcomes in 👥with #HF rEF published in Eur Heart J European Society of Cardiology Journals
🔥No evidence for an #obesity -survival paradox in #HF rEF
🔥📈adiposity defined by newer indices clearly associated with ⬆️ #HF 🏥

With ⬆️ data distinguishing HFmrEF from HFrEF and HFpEF, and new release of #PARAGONHF with subgroup analysis showing benefit if LVEF <= 57% (22%, consistent with #PARADIGMHF & #PIONEERHF ), is it time to see #Entresto HF outcomes studied in #HFmrEF ? #ESCcongress2019 #ACCPCardPRN

📣 #Heartfailure is common & costly & it results in considerable morbidity/mortality.
📍In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors ( #ARNI )➡️The Time Is Now?.
📌Its use ⤵️readmissions &⤴️survival
🔗jamanetwork.com/journals/jamac…

#PARADIGMHF #CHAMPHF #PIONEERHF

#PARADIGMHF #HeartFailure #cardiotwitter #MedTwitter

I may be overreacting, but this is overwhelming.
24/27 mth HF/Death
#COAPT #ParadigmHF
Preview slide SACJoven Sociedad Argentina de Cardiología Gregg W. Stone MD Oscar Mendiz Fabián Salmo Dr Roxana Mehran John Mandrola, MD

Dr Flores
Repasando beneficios en mortalidad d nuevos fármacos en IC (16% < en mortalidad). #lcz696 en #PARADIGMHF

Morning report Pearls from PGY2 Dr. Lee - Entresto with superior mortality benefit to ACE/ARB per the #PARADIGMHF trial

Prof. Małgorzata Lelonek: terapia niewydolności serca musi działać intensywnie i szybko - w innym przypadku możemy nie zdążyć ocalić pacjentowi życia: isbzdrowie.pl/2022/03/21531/ #niewydolnośćserca #flozyny #dapagliflozyna #Forxiga #DAPAHF #DAPACKD #PARADIGMHF #HFrEF

#TWILIGHT #DAPAHF #PARAGONHF #PARADIGMHF #COLCOT #PAH

#Sacubitril / #valsartan ( #Entresto ) significantly improved #heartfailure -related limitations affecting many #physical and #socialactivities compared with #enalapril , a #posthoc secondary #analysis of the #PARADIGMHF #trial showed.

Read more: qoo.ly/pam67

#ParadigmHF ARNI (angiotensin receptor–neprilysin inhibitor) for HF With Reduced
Ejection Fraction? No thanks

#PARADIGMHF Sac/Val vs Enalapril

✅ Benefits driven by large reductions in both HF events & death (RRR 16% ARR 2.8%)
pubmed.ncbi.nlm.nih.gov/26022006/

✅ Benefits consistently seen across 47 countries
ncbi.nlm.nih.gov/pmc/articles/P…

✅ Events blindly adjudicated using predetermined definitions

Excellent Tweetorial by Tony Breu describing #SGLT2i effects on ameliorating anemia

Curiously, similar observations w #ARNI sacubitril/vasartan in #PARADIGMHF

Might many effective HF therapies reduce hepcidin & improve systemic iron utilization?

sciencedirect.com/science/articl…

👇🏾

Sacubitril/valsartan: The PARADIGMHF study - ow.ly/DkWt30cNkwa #AUCardiologyReview

#SimPub with European Society of Cardiology #HeartFailure2022 in Circulation

How does health status change before & after a HF 🏥?

Protocolized serial #KCCQ in #PARADIGMHF & #PARAGONHF uncovered worsening health status in months prior to HF🏥 with only partial recovery after

ahajournals.org/doi/10.1161/CI…

So proud of Safia Chatur, MD on the stellar Young Investigator Award presentation with simultaneous publication in JACC Journals!

Effects of #ARNI in #HF across the Spectrum of Kidney Risk in #PARADIGMHF

jacc.org/doi/10.1016/j.…